Verve Therapeutics, Inc. – NASDAQ:VERV

Add to watchlist

$11.2

+5.18

+86.05%

Market open

Closed in about 5 hours

-10.55%

month

-10.55%

quarter

-58.96%

year

Market Cap	481.73M
Enterprise value	214.68M

P/E	-5.11
EV/Sales	110.60
EV/EBITDA	-1.40
Price/Sales	127.85
Price/Book	0.45
PEG ratio	0.16
EPS	-2.86

Revenue	16.04M
EBITDA	-217.22M
Income	-196.82M
Revenue Q/Q	305.62%
Revenue Y/Y	379.79%

Profit margin	-8108.55%
Oper. margin	-8536.17%
Gross margin	0%
EBIT margin	-8536.17%
EBITDA margin	-1353.5%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Verve Therapeutics Stock Forecast

M Q Y

Last Year

$14

Potential upside: 25.00%

Analysts Price target
Financials & Ratios estimates

Verve Therapeutics, Inc. (NASDAQ:VERV): Profit margin
Jun 2023	2.09M	-53.98M	-2579.22%
Sep 2023	3.11M	-45.75M	-1468.01%
Dec 2023	5.14M	-48.35M	-939.97%
Mar 2024	5.69M	-48.73M	-855.77%

Verve Therapeutics, Inc. (NASDAQ:VERV): Earnings per share (EPS)
2023-11-07	-0.91	-0.72
2024-02-27	-0.8	-0.69
2024-05-08	-0.68	-0.59

Verve Therapeutics, Inc. (NASDAQ:VERV): Debt to assets
Jun 2023	589131000	123.90M	21.03%
Sep 2023	612407000	152.03M	24.83%
Dec 2023	752688000	153.18M	20.35%
Mar 2024	732357000	149.28M	20.38%

Verve Therapeutics, Inc. (NASDAQ:VERV): Cash Flow
Jun 2023	-47.96M	33.02M	1.23M
Sep 2023	-11.81M	-11.83M	31.92M
Dec 2023	-40.68M	-8.89M	177.38M
Mar 2024	-43.08M	-41.63M	22.73M

Verve Therapeutics alternative data

Verve Therapeutics, Inc. (NASDAQ:VERV): Employee count
Aug 2023	204
Sep 2023	204
Oct 2023	204
Nov 2023	204
Dec 2023	204
Jan 2024	204
Feb 2024	204
Mar 2024	255
Apr 2024	255
May 2024	255
Jun 2024	255
Jul 2024	255

Verve Therapeutics
Hedge Funds Holdings Q1 2023

71.73% -28.27%

of VERV is owned by hedge funds

64 -55

hedge funds hold VERV stock

38.75M -23.86M

shares is hold by hedge funds

VERV hedge funds holdings changes

Verve Therapeutics
Insider Trading

Verve Therapeutics, Inc. (NASDAQ:VERV): Insider trades (number of shares)
Period	Buy	Sel
Apr 2024	0	1514
May 2024	76000	0
Dec 2024	0	555

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Dec 2024	DORVAL ALLISON officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	555	$5.64	$3,130
Option	29 Nov 2024	DORVAL ALLISON officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	1,875	N/A	N/A
Option	29 Nov 2024	DORVAL ALLISON officer: Chief Financial Officer officer: Chief Financial Officer	Restricted Stock Units	1,875	N/A	N/A
Option	28 Jun 2024	KATHIRESAN SEKAR director, officer..	Common Stock	30,000	$2.87	$86,100
Option	28 Jun 2024	KATHIRESAN SEKAR director, officer..	Stock Option (right to buy)	30,000	$2.87	$86,100
Purchase	14 May 2024	ASHE ANDREW D. officer: See Rema..	Common Stock	76,000	$6.26	$475,760
Sale	2 Apr 2024	NICKERSON JOAN officer: Chief Administrative Officer officer: Chief Administrative O..	Common Stock	1,514	$8.24	$12,475
Option	1 Apr 2024	NICKERSON JOAN officer: Chief Administrative Officer officer: Chief Administrative O..	Common Stock	3,315	N/A	N/A
Option	1 Apr 2024	NICKERSON JOAN officer: Chief Administrative Officer officer: Chief Administrative O..	Restricted Stock Units	3,315	N/A	N/A
Purchase	1 Dec 2023	YESHWANT KRISHNA director, 10 percent owner: director, 10 percent owner:	Common Stock	1,800,000	$10	$18,000,000

VERV insider trading transactions

Verve Therapeutics
Executives

Insider	Age	Compensation
Dr. Sekar Kathiresan M.D. (1972) Co-Founder, Chief Executive Officer & Director	53	$721,990
Mr. Andrew D. Ashe J.D. (1967) Pres & Chief Operating Officer	58	$532,690
Dr. Andrew Bellinger M.D., Ph.D. (1978) Chief Scientific Officer & Chief Medical Officer	47	$487,590
Dr. Burt A. Adelman M.D. (1952) Co-Founder & Independent Chairman	73	$60,000

Verve Therapeutics
Latest News

Thursday, 26 December 2024
10:00	Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation	accesswire.com
Sunday, 22 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation	accesswire.com
Wednesday, 18 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation	accesswire.com
Sunday, 15 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out	accesswire.com
Friday, 13 December 2024
10:15	VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm	accesswire.com
Friday, 29 November 2024
16:05	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 5 November 2024
09:16	Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Friday, 1 November 2024
16:26	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 28 October 2024
16:30	Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV	accesswire.com
12:30	VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	accesswire.com
10:00	VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm	prnewswire.com
10:00	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV	prnewswire.com
09:15	Lost Money on Verve Therapeutics, Inc. (VERV)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky	accesswire.com
07:00	FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com
05:45	Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV	prnewswire.com
Sunday, 27 October 2024
20:00	VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV	globenewswire.com
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV	accesswire.com
11:00	DEADLINE APPROACHING: Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm	accesswire.com
07:00	FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit!	accesswire.com
Saturday, 26 October 2024
11:00	The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Verve Therapeutics, Inc.	accesswire.com
09:00	VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV	businesswire.com
Friday, 25 October 2024
18:00	VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm	prnewswire.com
12:00	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV	prnewswire.com
09:50	SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics	prnewswire.com
Thursday, 24 October 2024
20:43	VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV	globenewswire.com
Wednesday, 23 October 2024
20:19	Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion	globenewswire.com
12:29	Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV	globenewswire.com
11:20	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERV	accesswire.com
11:15	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV	accesswire.com
11:00	Verve Therapeutics Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm	accesswire.com

Ideas & Opinions

Seeking Alpha 20 May 2025

I Missed The Quantum Rally - I Won't Miss The Next One
Seeking Alpha 16 Apr 2025

Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
Seeking Alpha 3 Apr 2024

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Seeking Alpha 29 Dec 2023

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
Seeking Alpha 11 Dec 2023

Verve: Potential To Advance Gene Based Editing Drugs For ASCVD
Seeking Alpha 11 Dec 2023

Verve Therapeutics: Revolutionizing Cardiovascular Health Via Gene Therapy
Seeking Alpha 30 Nov 2023

Verve Therapeutics: Lilly's Experience A Welcome Addition To In Vivo Gene Therapy Program
Seeking Alpha 10 Nov 2023

Beam Therapeutics: Sale Of Rights To Verve's In Vivo Candidates An Odd Decision
Seeking Alpha 4 Jul 2023

Verve: Exciting Deal With Eli Lilly, But Still Neutral (Reiterating Hold)
Seeking Alpha 20 May 2023

Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year

Frequently Asked Questions (FAQ)

What's the price of Verve Therapeutics stock today?

One share of Verve Therapeutics stock can currently be purchased for approximately $11.2.
When is Verve Therapeutics's next earnings date?

Unfortunately, Verve Therapeutics's (VERV) next earnings date is currently unknown.
Does Verve Therapeutics pay dividends?

No, Verve Therapeutics does not pay dividends.
How much money does Verve Therapeutics make?

Verve Therapeutics has a market capitalization of 481.73M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 505.77% to 11.76M US dollars. Verve Therapeutics made a loss 200.07M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
What is Verve Therapeutics's stock symbol?

Verve Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "VERV".
What is Verve Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Verve Therapeutics?

Shares of Verve Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Verve Therapeutics's key executives?
Verve Therapeutics's management team includes the following people:
- Dr. Sekar Kathiresan M.D. Co-Founder, Chief Executive Officer & Director(age: 53, pay: $721,990)
- Mr. Andrew D. Ashe J.D. Pres & Chief Operating Officer(age: 58, pay: $532,690)
- Dr. Andrew Bellinger M.D., Ph.D. Chief Scientific Officer & Chief Medical Officer(age: 47, pay: $487,590)
- Dr. Burt A. Adelman M.D. Co-Founder & Independent Chairman(age: 73, pay: $60,000)
Is Verve Therapeutics founder-led company?

Yes, Verve Therapeutics is a company led by its founders Dr. Sekar Kathiresan M.D. and Dr. Burt A. Adelman M.D..
How many employees does Verve Therapeutics have?

As Jul 2024, Verve Therapeutics employs 255 workers.
When Verve Therapeutics went public?

Verve Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 17 Jun 2021.
What is Verve Therapeutics's official website?

The official website for Verve Therapeutics is vervetx.com.
Where are Verve Therapeutics's headquarters?

Verve Therapeutics is headquartered at 500 Technology Square, Cambridge, MA.
How can i contact Verve Therapeutics?

Verve Therapeutics's mailing address is 500 Technology Square, Cambridge, MA and company can be reached via phone at +61 76030070.
What is Verve Therapeutics stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Verve Therapeutics in the last 12 months, the avarage price target is $14. The average price target represents a 25.00% change from the last price of $11.2.

Verve Therapeutics, Inc.

vervetx.com

Exchange:

NASDAQ

Full time employees:

255

Industry:

Biotechnology

Sector:

Healthcare

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

+61 76030070

500 Technology Square
Cambridge, MA 02139

CIK: 0001840574
ISIN: US92539P1012
CUSIP: 92539P101